Matthias Majetschak, MD, PhD

Surgery

Surgical Research
Molecular Pharmacology and Therapeutics
Associate Professor

Languages Spoken

English

Medical Education

Medical School
University of Duisburg-Essen, Germany
Residency
University Hospital
Essen
Germany - Surgery: General Surgery
Fellowship
University Hospital, Essen, Germany - Trauma Surgery

Research

  • Kv7.5 Potassium Channel Subunits Are the Primary Targets for PKA-Dependent Enhancement of Vascular Smooth Muscle Kv7 Currents Mani, B. K.; Robakowski, C.; Brueggemann, L. I.; Cribbs, L. L.; Tripathi, A.; Majetschak, M.; Byron, K. L., Molecular pharmacology
  • Commercially available antibodies directed against alpha-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments Tripathi, A.; Gaponenko, V.; Majetschak, M., Naunyn-Schmiedeberg's archives of pharmacology
  • Heteromerization of chemokine (C-X-C motif) receptor 4 with alpha1A/B-adrenergic receptors controls alpha1-adrenergic receptor function Tripathi, A.; Vana, P. G.; Chavan, T. S.; Brueggemann, L. I.; Byron, K. L.; Tarasova, N. I.; Volkman, B. F.; Gaponenko, V.; Majetschak, M., Proceedings of the National Academy of Sciences of the United States of America
View All ResearchShow Less
  • Kv7.5 Potassium Channel Subunits are the Primary Targets for PKA-Dependent Enhancement of Vascular Smooth Muscle Kv7 Currents Mani, B. K.; Robakowski, C.; Brueggemann, L. I.; Cribbs, L. L.; Tripathi, A.; Majetschak, M.; Byron, K. L., Molecular pharmacology
  • Proteasome Inhibition After Burn Injury Vana, P. G.; LaPorte, H. M.; Wong, Y. M.; Kennedy, R. H.; Gamelli, R. L.; Majetschak, M., Journal of burn care & research : official publication of the American Burn Association
  • Ubiquitin Urine Levels in Burn Patients Wong, Y. M.; LaPorte, H. M.; Albee, L. J.; Baker, T. A.; Bach, H. H., 4th; Vana, P. G.; Evans, A. E.; Gamelli, R. L.; Majetschak, M., Journal of burn care & research : official publication of the American Burn Association
  • Activities of nonlysosomal proteolytic systems in skeletal and cardiac muscle during burn-induced hypermetabolism Wong, Y. M.; La Porte, H. M.; Szilagyi, A.; Bach, H. H., 4th; Ke-He, L.; Kennedy, R. H.; Gamelli, R. L.; Shankar, R.; Majetschak, M., Journal of burn care & research : official publication of the American Burn Association
  • Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular alpha(1)-adrenergic receptor function Bach, H. H., 4th; Wong, Y. M.; Tripathi, A.; Nevins, A. M.; Gamelli, R. L.; Volkman, B. F.; Byron, K. L.; Majetschak, M., Molecular medicine (Cambridge, Mass.)
  • CXC chemokine receptor 4 signaling upon co-activation with stromal cell-derived factor-1alpha and ubiquitin Tripathi, A.; Davis, J. D.; Staren, D. M.; Volkman, B. F.; Majetschak, M., Cytokine
  • Differential protein kinase C-dependent modulation of Kv7.4 and Kv7.5 subunits of vascular Kv7 channels Brueggemann, L. I.; Mackie, A. R.; Cribbs, L. L.; Freda, J.; Tripathi, A.; Majetschak, M.; Byron, K. L., The Journal of biological chemistry
  • Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases Baker, T. A.; Bach, H. H., 4th; Gamelli, R. L.; Love, R. B.; Majetschak, M., Physiological Research / Academia Scientiarum Bohemoslovaca
  • Modulation of the CXC chemokine receptor 4 agonist activity of ubiquitin through C-terminal protein modification Tripathi, A.; Saini, V.; Marchese, A.; Volkman, B. F.; Tang, W. J.; Majetschak, M., Biochemistry
  • Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats Bach, H. H., 4th; Laporte, H. M.; Wong, Y. M.; Gamelli, R. L.; Majetschak, M., The journal of trauma and acute care surgery
  • Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma. Baker, T. A.; Romero, J.; Bach, H. H., 4th; Strom, J. A.; Gamelli, R. L.; Majetschak, M., Critical care medicine
  • Initial assessment of the role of CXC chemokine receptor 4 after polytrauma Bach, H. H., 4th; Saini, V.; Baker, T. A.; Tripathi, A.; Gamelli, R. L.; Majetschak, M., Molecular Medicine
  • Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage Baker, T. A.; Romero, J.; Bach, H. H., 4th; Strom, J. A.; Gamelli, R. L.; Majetschak, M., Critical care medicine
  • Ubiquitin and stromal cell-derived factor-1alpha in bronchoalveolar lavage fluid after burn and inhalation injury. Baker, T. A.; Davis, C. S.; Bach, H. H., 4th; Romero, J.; Burnham, E. L.; Kovacs, E. J.; Gamelli, R. L.; Majetschak, M., Journal of Burn Care & Research
  • Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules Majetschak, M., Journal of leukocyte biology
  • Structural determinants of ubiquitin-CXC chemokine receptor 4 interaction Saini, V.; Marchese, A.; Tang, W. J.; Majetschak, M., The Journal of biological chemistry
  • The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1alpha function through distinct receptor interactions. Saini, V.; Staren, D. M.; Ziarek, J. J.; Nashaat, Z. N.; Campbell, E. M.; Volkman, B. F.; Marchese, A.; Majetschak, M., Journal of Biological Chemistry
  • Circulating proteasomes after burn injury. Majetschak, M.; Zedler, S.; Romero, J.; Albright, J. M.; Kraft, R.; Kovacs, E. J.; Faist, E.; Gamelli, R. L., Journal of Burn Care & Research
  • CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. Saini, V.; Marchese, A.; Majetschak, M., Journal of Biological Chemistry
  • Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation Baker, T. A.; Geng, Q.; Romero, J.; Picken, M. M.; Gamelli, R. L.; Majetschak, M., Biochemical and biophysical research communications
  • Ubiquitin receptor binding and signaling in primary human leukocytes Saini, V.; Romero, J.; Marchese, A.; Majetschak, M., Communicative & integrative biology
  • A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Geng, Q.; Romero, J.; Saini, V.; Baker, T. A.; Picken, M. M.; Gamelli, R. L.; Majetschak, M., Biochemical & Biophysical Research Communications
  • Detection and possible role of proteasomes in the bronchoalveolar space of the injured lung. Majetschak, M.; Sorell, L. T.; Patricelli, T.; Seitz, D. H.; Knoferl, M. W., Physiological Research
  • Proteasomes in human bronchoalveolar lavage fluid after burn and inhalation injury Albright, J. M.; Romero, J.; Saini, V.; Sixt, S. U.; Bird, M. D.; Kovacs, E. J.; Gamelli, R. L.; Peters, J.; Majetschak, M., Journal of Burn Care & Research
  • Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus. Majetschak, M.; Perez, M.; Sorell, L. T.; Lam, J.; Maldonado, M. E.; Hoffman, R. W., Clinical & Vaccine Immunology: CVI
  • Immunological methods to quantify and characterize proteasome complexes: development and application. Majetschak, M.; Sorell, L. T., Journal of immunological methods

Research Interests: New therapeutic approaches to critical illness

The main goal of research in the Majetschak laboratory is to identify molecular targets for new therapeutic approaches, which are aimed to improve cardiovascular function and reduce secondary organ dysfunction and damage in critical illness. A main focus is the understanding of the mechanisms which contribute to the development of hemodynamic instability, impairment of cardiopulmonary function and development of (multiple) organ dysfunction and failure. Current research is focused 1) on the role of the intracellular ubiquitin proteasome pathway of protein degradation during the local and systemic response to tissue injury and 2) on the role of the SDF-1a (CXCL12)/Ubiquitin-CXCR4/CXCR7 axis during trauma and shock.
Our approach is clinically oriented, integrative and translational in nature. Utilizing initial observations in patients to develop novel hypotheses, we establish cell systems to determine underlying molecular mechanisms, which are then probed for therapeutic applicability in in vivo models to provide proof of concept, followed by rigorous preclinical efficacy testing to enable transition towards clinical applicability.

View a partial list of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=Majetschak+M%5BAuthor+Name%5D&doptcmdl=DocSum target=_blank>Dr. Majetschak's publications through the National Library of Medicine's PubMed online database.